Skip to main content
Erschienen in: Arthritis Research & Therapy 4/2011

01.08.2011 | Editorial

Are we ready for therapeutic drug monitoring of biologic therapeutics?

verfasst von: Charlotte LM Krieckaert, Willem F Lems

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

In the previous issue of Arthritis Research & Therapy, Ducourau and colleagues report that they retrospectively detected anti-infliximab antibodies in 21% of patients with rheumatic diseases. Patients with anti-infliximab antibodies had lower serum drug concentrations. These findings contribute to the existing evidence of immunogenicity of biologicals and its clinical relevance. We argue for therapeutic drug monitoring to optimize treatment response.
Literatur
1.
Zurück zum Zitat Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011, 13: R105-10.1186/ar3386.PubMedCentralCrossRefPubMed Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011, 13: R105-10.1186/ar3386.PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011, 305: 1460-1468. 10.1001/jama.2011.406.CrossRefPubMed Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011, 305: 1460-1468. 10.1001/jama.2011.406.CrossRefPubMed
3.
Zurück zum Zitat Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003, 348: 601-608. 10.1056/NEJMoa020888.CrossRefPubMed Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003, 348: 601-608. 10.1056/NEJMoa020888.CrossRefPubMed
4.
Zurück zum Zitat Karmiris K, Paintaund G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P: Influence of trough serum levels and immumogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009, 137: 1628-1640. 10.1053/j.gastro.2009.07.062.CrossRefPubMed Karmiris K, Paintaund G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P: Influence of trough serum levels and immumogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009, 137: 1628-1640. 10.1053/j.gastro.2009.07.062.CrossRefPubMed
5.
Zurück zum Zitat Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011, 50: 1445-1452. 10.1093/rheumatology/ker124.CrossRef Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011, 50: 1445-1452. 10.1093/rheumatology/ker124.CrossRef
6.
Zurück zum Zitat Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ: Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011, 63: 877-883. 10.1002/art.30209.CrossRefPubMed Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ: Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011, 63: 877-883. 10.1002/art.30209.CrossRefPubMed
7.
Zurück zum Zitat Wolbink GJ, Aarden LA, Dijkmans BA: Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009, 21: 211-215. 10.1097/BOR.0b013e328329ed8b.CrossRefPubMed Wolbink GJ, Aarden LA, Dijkmans BA: Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009, 21: 211-215. 10.1097/BOR.0b013e328329ed8b.CrossRefPubMed
8.
Zurück zum Zitat Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ: The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010, 12: 217-10.1186/ar3147.PubMedCentralCrossRefPubMed Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ: The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010, 12: 217-10.1186/ar3147.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25: 40-46.PubMed Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25: 40-46.PubMed
10.
Zurück zum Zitat Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259. 10.1056/NEJM199901283400401.CrossRefPubMed Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259. 10.1056/NEJM199901283400401.CrossRefPubMed
11.
Zurück zum Zitat Jamnitski A, Hart M, Nurmohamed MT, Krieckaert C, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ: Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients [abstract]. Ann Rheum Dis. 2011, 70 (Suppl 3): 119- Jamnitski A, Hart M, Nurmohamed MT, Krieckaert C, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ: Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients [abstract]. Ann Rheum Dis. 2011, 70 (Suppl 3): 119-
Metadaten
Titel
Are we ready for therapeutic drug monitoring of biologic therapeutics?
verfasst von
Charlotte LM Krieckaert
Willem F Lems
Publikationsdatum
01.08.2011
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 4/2011
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3395

Weitere Artikel der Ausgabe 4/2011

Arthritis Research & Therapy 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.